Lv3
210 积分 2025-07-22 加入
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study
19天前
已完结
IgG4-related disease: an update on pathophysiology and implications for clinical care
27天前
已完结
Clinical Perspectives on IgG4-Related Disease and Its Classification
27天前
已完结
Meta-Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
2个月前
已完结
Crohn’s disease and ulcerative colitis exhibit prediagnostic antibody signatures with shared and divergent changes towards disease onset
3个月前
已完结
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
3个月前
已完结
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design
3个月前
已完结
Development and validation of peripheral blood DNA methylation signatures to predict response to biological therapy in adults with Crohn's disease (EPIC-CD): an epigenome-wide association study
3个月前
已完结
Progress in validation of treatment-response biomarkers in Crohn's disease?
3个月前
已完结
Crohn's disease and ulcerative colitis exhibit prediagnostic antibody signatures with shared and divergent changes towards disease onset
3个月前
已关闭
皖公网安备34019202002308
